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The primary role of the human neutrophil is to 
destroy pathogenic microbes that have invaded the 
host [I, 2]t. Neutrophils accomplish this task by 
using their plasma membrane to engulf and sequester 
the microorganisms into the formed intracellular 
compartment which is termed the phagocytic 
vacuole. Simultaneous with the initiation of vacuole 
formation, a portion of the lysosomal granules of the 
neutrophil fuse with the encircling plasma membrane 
and discharge their complement of microbicidal pro- 
teins and proteases. In addition, a plasma mem- 
brane-associated NADPH oxidase is activated which 
consumes dissolved 02 in order to generate a com- 
plex array of highly reactive oxidants. Together, 
the lysosomal contents and the oxygen metabolites 
efficiently participate in the destruction and degra- 
dation of the target. 
Although the neutrophil is heavily girded for 
microbial battle, it is also known that the cell contains 
intracellular organelles whose contents are destined 
for extracellular discharge [3]. In this commentary 
we will discuss the potential functions of two oft- 
neglected metalloproteinases that are released from 
triggered neutrophils, collagenase and gelatinase. 
These enzymes are able to specifically degrade the 
collagens, a family of closely related, but distinct 
macromolecules that comprise the major structural 
proteins of all connective tissues [4,5]. Given the 
* Author to whom all correspondence should be 
addressed. 
t Whenever possible, readers will be referred to review 
articles or to recent publications where additional ref- 
erences can be found. 
$ Type I collagen is the most ubiquitous type of collagen 
in adult connective tissues and is found primarily in skin, 
bone, tendon, gingiva, large blood vessels and the uterine 
wall. Type III collagen has a tissue distribution similar to 
type I except that it is found in only small amounts in bone, 
tendon, and cornea. Type II collagen is primarily confined 
to the nucleus pulposus, hyaline cartilage and vitreous. 
For more extensive reviews on collagen distribution and 
chemistry, see Refs. 4 and 5. 
$ A recent exception is the collagenase isolated from the 
rat uterus (111. 
apparent substrate specificity of the metalloenzymes, 
it seems clear that they do not exert a direct micro- 
bicidal effect, but their precise function in neutrophil 
physiology remains unclear. Indeed, despite the fact 
that the role of similar collagenolytic enzymes in 
physiologic and pathologic tissue degradation [6,7], 
angiogenesis [8,9] and tumor metastasis [lo] is under 
intense scrutiny, few of these insights have been 
applied to our understanding of neutrophil function 
in host defense and inflammation. What are the 
characteristics of the neutrophil metalloenzymes? 
How are they regulated by the intact cell? What are 
their physiologic functions in vivo? By examining 
these questions we hope to focus attention on 
enzymes that potentially play critical roles in the 
regulation of cell movement and tissue degradation 
in health and disease. 
What are the characteristics of neutrophil collagenme? 
The triple helix of the interstitial collagens (i.e. 
types I, II, and III)+ confers these macromolecules 
with a high degree of resistance against general pro- 
teases [4-71. However, a number of mammalian cells 
including skin and synovial fibroblasts, uterine cells, 
bone cells, chondrocytes, macrophages and endo- 
thelial cells can synthesize and secrete “classic” ver- 
tebrate collagenases, i.e. they cleave native inter- 
stitial collagen at neutral pH and at only one specific 
locus within the helix 314 from the amino terminus 
[4-71. In terms of its general properties, the neu- 
trophil collagenase shares many characteristics with 
the more extensively studied tissue collagenases. All 
of these collagenases are calcium- and zinc-requiring 
enzymes, have neutral pH optima and express a 
strong preference for native, rather than denatured, 
collagens [6,7].§ Despite these similarities, the neu- 
trophil collagenase distinguishes itself from other 
collagenases by the fact that (1) the neutrophil col- 
lagenase is stored in a secretory granule and is not 
actively synthesized by the mature cell [6], (2) the 
neutrophil collagenase is structurally distinct and can 
be identified with monoclonal antibodies that do not 
identify other tissue collagenases [12], and (3) the 
neutrophil proteinase has a different substrate speci- 
ficity for the individual collagen types [6, 131. 
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What is the molecular basis for the latency of neu- 
trophil collagenase? 
One of the most intriguing aspects of the phy- 
sicochemical properties of neutrophil collagenase is 
the fact that the enzyme can be isolated from the cell 
in a latent, inactive form [6,7,13]. This latency is 
not a general property of other lysosomal enzymes 
found in the neutrophil, but rather a characteristic 
of most, if not all, mammalian collagenases [6,7]. 
All of the latent collagenases can be activated in 
vitro by an array of seemingly unrelated and many 
times physiologically irrelevant proteases (e.g. tryp- 
sin), thiol-reactive organomercurials (e.g. 4-amino- 
enzyme is likewise a zymogen. However, a series of 
reports by Macartney and Tschesche [17-191 have 
marshalled support for the classification of neu- 
trophil collagenase as an enzyme-inhibitor complex. 
Highly purified neutrophil collagenase was isolated 
as a 91 kilodalton (kD) latent enzyme that could be 
activated by either organomercurials or disulfides to 
yield active collagenase with an M, of 64 kD and, 
in addition, a 24 kD inhibitor [19]. The inhibitor 
contained a single essential thiol, inactivated col- 
lagenase with an apparent 1: 1 stoichiometry, and 
lost activity if incubated with a disulfide [17-191. 
Based on these findings, the following model was 
proposed: 
/-S-Inhibitor + X-S-S-X 
E’SH 








phenylmercuric acetate) and chaotropic agents [6,7]. 
In an attempt to explain these characteristics, the 
latent enzyme has been proposed to be either a 
proenzyme or an enzyme-inhibitor complex 
[6,7,14]. The proenzyme model was based on the 
observation that proteases activate latent collagenase 
while simultaneously decreasing its apparent mol- 
ecular weight [6,7,14]. However, organomercurials 
and chaotropic agents also activate and decrease the 
molecular weight of the latent enzyme [6,7,14]. 
Because these compounds do not possess an intrinsic 
ability to mediate peptide bond cleavage, the data 
seemed to indicate that the enzyme was activated 
following the dissociation of an inhibitor. This 
controversy has been resolved recently in at least two 
cases. Studies with highly purified skin and synovial 
fibroblast collagenases have revealed that these 
metalloproteinases are proenzymes [6]. Organo- 
mercurials and chaotropic agents indirectly decrease 
the M, of the skin collagenase by perturbing the 
conformation of the zymogen and unmasking an 
intrinsic, autocatalytic potential [15]. This allows the 
activated collagenase to then catalyze an intra- 
molecular cleavage that is not a prerequisite for 
activation [15]. In contrast, synovial collagenase is 
activated indirectly after a proteinase or an organo- 
mercurial activates a latent proactivator which then 
acts on the procollagenase [6]. Under certain con- 
ditions, both the skin and synovial procollagenases 
can be shown to undergo activation without any 
detectable change in their molecular weights [6,15]. * 
If highly purified, latent procollagenases can be 
activated by exogenous proteinases, organomer- 
curials and chaotropic conditions, one might assume 
that the ability of these agents to also activate neu- 
trophil collagenase would indicate that this latent 
* As indicated by these investigators, small decreases in 
M, (< 2000) may not be detected. For example, trypsinogen 
is a proenzyme that is activated following the removal of 
only the N-terminal hexapeptide [16]. 
(64-kD) (24 kD) 
Thus, the latent enzyme was postulated to contain a 
disulfide-linked inhibitor and a free thiol. Following 
the addition of a disulfide, a series of thiol-disulfide 
exchanges occurred leading to the generation of the 
proposed disulfide-bridged active enzyme and an 
inactive disulfide-linked inhibitor. In support of this 
model, incubation of the activated collagenase with 
inhibitor regenerated latent collagenase with an 
apparent molecular weight of - 90 kD when esti- 
mated by gel filtration [19]. These data provide com- 
pelling evidence to support the contention that neu- 
trophil collagenase is an enzyme-inhibitor complex 
and have led to the proposal that physiological 
changes in the thiol-disulfide redox couple might 
regulate neutrophil collagenase in vivo. However, 
the fact that all other well-characterized collagenases 
are proenzymes suggests that a cautious appraisal of 
these data is warranted. First, the presence of a thiol 
in the dissociated inhibitor has been demonstrated, 
but the model also predicts that the latent collagenase 
should contain a free thiol. The ability of the thiol- 
reactive organomercurials or disulfides to activate 
collagenase suggests that the latent enzyme might 
have a reactive thiol moiety, but this cannot be 
assumed. Indeed, although skin collagenase can be 
activated by organomercurials or disulfides, it is not 
an enzyme-inhibitor complex and does not contain 
any detectable thiols [15,20]. Second, much of the 
early support for the concept that tissue collagenases 
were enzyme-inhibitor complexes was based on the 
fact that an excess of an inhibitor could also be 
detected in these cell culture media [ 141. In a manner 
similar to the neutrophil system, the inhibitor formed 
a 1: 1 complex with active collagenase to generate 
a species with characteristics that appeared almost 
identical to the original latent enzyme [ 141. However, 
subsequent studies have demonstrated that the 
inhibitor is a distinct gene product, that it is not 
structurally related to the proenzyme, and that 
although it can be demonstrated to bind the active 
enzyme when assessed by gel filtration, it does not 
form a sodium dodecylsulfate (SDS)-stable complex 
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[21-23].* Finally, it is difficult to rule out the possi- 
bility that neutrophil collagenase, like the tissue col- 
lagenases, is actually a proenzyme, but that it has 
undergone activation during its extraction from dis- 
rupted neutrophils. Following activation, the enzyme 
might then interact with a normally sequestered, 24 
kD endogenous inhibitor that results in the isolation 
of the “latent” collagenase as an enz~e-inhibitor 
complex. Indeed, this proposed scenario has a prece- 
dent. Much of the thiol-disulfide model of neutrophil 
collagenase activation is based on an earlier series 
of reports by Steven and Podrazky [24,25] on the 
regulation of a tumor cell protease. In a strikingly 
similar system, Ehrlich ascites tumor cells were 
shown to contain a trypsin-sensitive, latent neutral 
protease in their granular fractions and a thiol-con- 
taining protease inhibitor in the cytosolic post-gran- 
ule supernatant fraction [24,25]. If a similar com- 
partmentalization occurs in the intact neutrophil, it 
will be important to analyze latent collagenase that 
has been rigorously prevented from interacting with 
cytosolic or other granule-isolated factors. Indeed, 
Hasty et al. 1261 may have circumvented this problem 
by isolating the collagenase that was released directly 
from intact triggered neutrophils. Using a com- 
bination of immunoaffinity chromatography and 
immunoblotting, neutrophil collagenase could be 
identified in latent forms with molecular weights of 
75K and 57K [26]. Not only are these molecular 
weights substantially lower than the 91 kD species 
described by Macartney and Tschesche, but these 
two forms of collagenase could be activated by a 
chaotropic agent (NaSCN) without undergoing a 
detectable decrease in M, [26]. Additional analyses 
of the stored latent collagenase and the com- 
partmentalization of its inhibitor will be required 
before these differences can be resolved. 
Can neutrophils activate latent collagenare and, ifso, 
how? 
Regardless of the molecular basis underlying the 
latency of neutrophil collagenase, it is clear that the 
enzyme must be activated in an intact cell system 
before it can catalyze collagen degradation. 
Although a variety of processes have been postulated 
to play potential roles in the activation of neutrophil 
collagenase [6,7], only a handful of studies have 
actually examined the regulation of the enzyme in 
an intact cell system [12,27,28]. Until recently, the 
accumulated data suggested that neutrophils could 
release latent collagenase extracellularly, but that 
the cells have almost no intrinsic ability to activate 
* It should be noted that activation fragments released 
from zymogens can exert inhibitory effects on the active 
enzyme. For example, porcine pepsinogen is converted to 
enzymatically active pepsin by the loss of its 44 amino- 
terminal residues. This peptide can then be degraded by 
pepsin to generate potent inhibitors [16]. Thus, in such a 
system, enzyme activation could take on the appearance of 
the dissociation of an enzyme-inhibitor complex. 
i These results contrast with those of Ebbs and co- 
workers [ 123 where PMA-stim~ated neutrophils were not 
reported to release active collagenase. It is unclear why 
these investigators failed to detect the active collagenase. 
the enzyme [12,27,28]. (Indeed, it seems that the 
apparent inability of the neutrophil to activate its 
collagenase stifled further interest in the enzyme.) 
Perplexed by these observations, our group re-exam- 
ined the ability of human neutrophils to release and 
activate endogenous coliagenase 1291. In contrast 
to other studies, we demonstrated that neutrophils 
incubated with phorbol myristate acetate (a non- 
physiologic triggering agent that stimulates neu- 
trophils to discharge granules and generate oxygen 
metabolites in a manner that mimics physiologic 
stimuli) or opsonized zymosan particles (an ingest- 
able particle coated with plasma proteins that are 
recognized by receptors on the neutrophil 
membrane) activated - 50% of the released 
collagenase? [29]. These results clearly demonstrated 
that neutrophils could directly activate latent col- 
lagenase, but how was this accomplished? 
Endogenously-derived serine proteinases, metal- 
loproteinases, as well as non-proteolytic activators 
have been shown to play important roles in the 
a~ivation of latent collagenases released by mouse 
bone cultures, alveolar macrophages, rheumatoid 
synovial cells, uterine and skin cells and even tumor 
cells [6,7,30]. In the neutrophil, early attention 
focused on the ability of the cell’s two major serine 
proteinases, elastase and cathepsin G, to activate 
collagenase [13,31]. However, studies with the iso- 
lated enzymes demonstrated that these enzymes 
actually destroy neutrophil collagenase [13]. Rather 
than focus our attention on potential protease- 
dependent mechanisms of activation, we became 
intrigued with the possibility that the ability of 
organomercurials to activate colfagenase might pro- 
vide a clue to the identity of the endogenous 
activator(s~ generated by the neutrophil. Unlike 
almost all other cell types, the neutrophil not only 
releases lysosomal enzymes but also generates a fam- 
ily of highly reactive oxygen metabolites [l, 321. In 
a series of catalyzed and spontaneous reactions, the 
triggered neutrophil generates superoxide anion 
(O;), hydrogen peroxide (HzOz), hypochlorous acid 
(HOCl) and possibly the hydroxyl radical [l, 321. 
Was it possible that microbicidal oxidants might func- 
tion as “endogenous organomercurials” and activate 
collagenase by reacting with a critical thiol[17-191 or 
by perturbing its normal conformation [15]? Strong 
support for the participation of oxidants in col- 
lagenase activation was quickly provided from analy- 
ses of neutrophils isolated from individuals with 
chronic granulomatous disease [29]. This genetic dis- 
order is characterized by the inability of the neu- 
trophil to generate oxygen metabolites [l]. In con- 
trast to our findings with normal neutrophils, the 
chronic granulomatous disease cells were only able 
to release latent collagenase and none of the enzyme 
could be detected in its active state [29]. These results 
clearly defined a critical requirement for oxygen 
metabolites in the expression of collagenolytic 
activity. Further studies with normal neutrophils led 
to the identification of HOC1 as the key oxidant in 
the activation pathway 1291. This highly reactive 
oxidant (the active ingredient in bleach) is generated 
by a reaction dependent on HzOz, the lysosomal 
enzyme myeloperoxidase (a green hemoprotein that 
gives pus its distinctive color) and chloride (equation 
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2; Refs. 1 and 32): 
H202 + Cl- + H + mye’ope’oxrdar~ HOC1 + HZ0 (2) 
If neutrophils were triggered in the presence of cata- 
lase (consumes H202), azide (inhibits myelop- 
eroxidase) or methionine (a competitive scavenger 
of HOCl), active collagenase could not be detected 
[29]. However, if these cell-free supernatant frac- 
tions were incubated with the organomercurial, 4- 
aminophenylmercuric acetate, or with reagent 
HOCl, the latent collagenase was activated [29]. 
Thus, neutrophils could activate their endogenous 
collagenase, and the activation process was linked to 
the generation of HOCI. 
Is HOC1 the final mediator in the activation sequence? 
Regardless of the sequence of events that link 
HOC1 generation to collagenase activation (see 
below), it is difficult to identify HOC1 as the “final” 
mediator. Although HOC1 is the final oxidant gen- 
erated by the myeloperoxidase system, in a complex 
cell system the generated HOC1 also participates in 
secondary reactions [33-351. For example, HOC1 
can react with endogenous amines that are simul- 
taneously released from the neutrophil to generate 
N-chloroamines (equation 3). 
RNHr + HOC1 > RNHCl + H2 0 
These chlorinated products are two electron oxidants 
whose reactivity is partially dictated by the R group 
[33-351. N-Chloroamines may be hydrophobic or 
hydrophilic, stable or unstable [33-351. These deriva- 
tive oxidants might mediate collagenase activation, 
but preliminary studies with N-chlorotaurine, the 
major hydrophilic N-chloroamine generated by the 
neutrophil [34,35], indicate that this species is not 
as effective an activator as HOC1 [29]. However, the 
fact that an oxidant with limited reactivity relative 
to HOC1 (e.g. N-chlorotaurine preferentially reacts 
with thiols and thioethers at neutral pH) can partially 
activate collagenase may provide additional insights 
into the chemical basis of activation. 
In considering the role that HOC1 plays in col- 
lagenase activation, our attention should not necess- 
arily be limited to the direct effects exerted by chlori- 
nated oxidants. For example, HOC1 or RNCl can 
oxidize thiols to disulfides and these products have 
been proposed to act as collagenase activators [17- 
191. In a model system designed to mimic the intact 
cell, Tschesche and Macartney demonstrated that 
collagenase could be reversibly shifted from a latent 
to an active form depending on the ratio of glu- 
tathione (GSH) to oxidized glutathione (GSSG; Ref. 
18). Oxidation of GSH to GSSG can be mediated by 
a variety of peroxidases including myeloperoxidase, 
glutathione peroxidase, horseradish peroxidase and 
lactoperoxidase [18]. Subsequently, the generated 
GSSG activates the latent collagenase by dissociating 
the putative enzyme-inhibitor complex (see 
equation 1). (This study is often misinterpreted by 
other investigators as indicating that cell-derived oxi- 
dants directly regulated collagenase activity. 
Actually, the HrOr-myeloperoxidase-Cl-system was 
incapable of activating collagenase unless exogenous 
GSH was oxidized to GSSG. Thus, peroxidases that 
do not release oxidants directly, e.g. glutathione 
peroxidase, were also capable of activating latent 
collagenase as long as they generated GSSG.) They 
concluded that alterations in the GSH/GSSG ratio 
that occur in triggered neutrophils would then regu- 
late collagenase activity, but we consider this possi- 
bility unlikely. Decreases in GSH associated with 
phagocytosis are quite small (normal levels fall by 
- 30%) and only a portion of the lost GSH can 
be accounted for as GSSG [36]. In addition, the 
oxidation of GSH occurs in the cytosol[36], and it is 
not clear how GSSG might gain access to collagenase 
that has been released into the phagocytic vacuole 
or extracellularly. GSSG generated in the cytosol 
could be transported extracellularly [36], but we 
are unaware of any studies that have demonstrated 
GSSG efflux in the neutrophil. Finally, other inves- 
tigators have been unable to demonstrate that GSSG 
can activate latent collagenase that had been released 
from neutrophils [29,37]. At this time, a role for 
intracellular disulfides in the activation process 
remains unclear, but neutrophils can oxidize extra- 
cellular thiols present in plasma [38]. Thus, the possi- 
bility that these disulfides might regulate endogenous 
as well as exogenous collagenase activity at inflamed 
sites deserves careful attention. 
How might HOC1 regulate latent collagenase? 
The mechanism(s) by which HOC1 or HOCl- 
derived products activate collagenase is unknown. 
Ultimately, an elucidation of the reaction scheme 
underlying activation will depend on the construct 
of the latent collagenase as a proenzyme, an enzyme- 
inhibitor complex, or a combination of proenzyme 
and inhibitor. First, in the proenzyme model, HOC1 
could mimic the action of the organomercurials and 
directly activate latent procollagenase [6] or a latent 
activator of procollagenase [6,39]. That is, HOCI- 
mediated oxidations or chlorinations could cause 
conformational changes in the targeted molecule 
which result in the activation of neutrophil colla- 
genase. Second, if neutrophil collagenase is an 
enzyme-inhibitor complex, then HOC1 could act by 
simply oxidizing the critical thiol proposed to control 
the dissociation of the inhibitor [17-191. However, 
this model is complicated by the fact that Hasty et 
al. [26] could not detect the predicted 91 kD enzyme- 
inhibitor collagenase complex in supernatant frac- 
tions recovered from triggered neutrophils. Finally, 
if the neutrophil releases procollagenase and an inde- 
pendently functioning inhibitor of activated col- 
lagenase, a different scenario could be envisioned in 
which HOC1 does not directly participate in col- 
lagenase activation. In this model, the proenzyme 
would be activated by an uncharacterized oxygen- 
independent process, but collagenolytic activity 
would not be detected unless the simultaneously 
released collagenase inhibitor was oxidatively 
destroyed. This model is not without precedent. 
Neutrophils contain large amounts of the lysosomal 
serine proteinase, elastase. Unlike collagenase, elas- 
tase is stored and released in an active form [40]. 
However, under physiological conditions, elastase 
activity is carefully regulated by the plasma anti- 
proteinase, alpha-1-proteinase inhibitor (o-l-PI; 
Ref. 41). In turn, a-l-PI activity can be inhibited by 
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cell-derived chlorinated oxidants [40]. Thus, in a 
manner analogous to the proposed collagenase 
system, the elastase activity released by triggered 
neutrophils cannot be detected in the presence of LY- 
l-PI unless the activity of the antiproteinase has 
been oxidatively down-regulated. In contrast to the 
elastase-a-1-R system, the latent collagenase would 
first be required to undergo activation and the oxid- 
izable inhibitor would necessarily be of endogenous 
origin. Interestingly, collagenase inhibitors have 
been described in the cytosol of human neutrophils, 
but their characteristics and potential extracellular 
release have not been examined [31,42]. 
Could other factors play a role in collagenase 
activation? 
The inability of chronic granulomatous disease 
neutrophils to activate significant amounts of col- 
lagenase indicated that alternate, oxygen-indepen- 
dent mechanisms of activation were not operative in 
our system [29]. However, it should be noted that 
cells were triggered for only short periods of time 
and in the absence of the collagen substrate (i.e. only 
the cell-free supernatant fractions were assayed for 
collagenase activity) or exogenous plasma factors 
[29]. Under these conditions, potential roles for col- 
lagenase autoactivation, substrate-dependent acti- 
vation, or membrane-associated collagenase activity 
would not have been assessed, but do deserve con- 
sideration [6,7]. In addition, neutrophils are gen- 
erally considered to be devoid of any biosynthetic 
activity, but they are able to synthesize a number of 
proteins including plasminogen activator [43-45]. 
This serine proteinase can cleave the plasma protein 
plasminogen to form plasmin. In turn, plasmin has 
been shown to activate a number of tissue col- 
lagenases [6,7]. In a preliminary study, we reported 
that neutrophils triggered in the presence of exogen- 
ous plasminogen did not activate collagenase by a 
plasmin-dependent process 1291, but the conditions 
chosen may have been sub-optimal [45]. Further- 
more, a search for additional activators should not 
necessarily be limited to endogenous factors. For 
example, early studies demonstrated that rheu- 
matoid synovial fluids [46,47] and dental plaque [48] 
contain factors that activated crude preparations of 
neutrophil collagenase. Indeed, the many similarities 
between the latent collagenases suggest that the abil- 
ity of activators identified in other cell systems (e.g. 
kallikrein, cathepsin, and angiogenesis factors), to 
regulate neutrophil collagenase should also be con- 
sidered [6,7,14]. Similarly, it will be interesting to 
determine if neutrophil-derived oxidants can activate 
other tissue collagenases or if exogenously intro- 
duced oxidants (e.g. cigarette smoke [49]; reagent 
HzOz [SO]) could also participate in the regulation of 
collagenase activity. 
Characteristics of neutrophil gelatinase 
Neutrophils contain a second metalloproteinase, 
gelatinase, [42,51,52], with characteristics similar to 
the gelatinase synthesized by a variety of connective 
tissue cells [53]. Like collagenase, neutrophil gela- 
tinase is a latent enzyme, requires calcium and zinc 
for maximal activity, and possesses a neutral pH 
optimum [52]. However, unlike collagenase, neu- 
trophil gelatinase is stored in an independently con- 
trolled secretory compartment and has a unique sub- 
strate specificity [13,52]. Gelatinase does not attack 
native interstitial collagens, but can degrade de- 
natured collagen (i.e. gelatin) as well as native type 
IV or type V collagen [13,52]. 
Neutrophil gelatinase was first isolated in 1974 
[54], and since that time a range of molecular weights 
and characteristics have been reported [52]. In the 
most recent study, Hibbs et al. [52] purified the latent 
enzyme released from triggered neutrophils by a 
combination of anion exchange and gelatin-affinity 
chromatography. Three bands with gelatinase 
activity could be identified on non-reduced gels with 
molecular weights of 92K, 130K and 225K. Upon 
reduction, all forms migrated as a single 92K band. 
These authors concluded that the multiple molecular 
weight forms were derived from a single proteinase, 
but they could not rule out the possibility that the 
enzyme had undergone cellular processing during 
secretion [52]. 
The molecular basis underlying the latency of gela- 
tinase has not been studied as extensively as that 
for collagenase, but latent gelatinase can also be 
activated by proteases, organomercurials and chao- 
tropicagents [13,51,52,54]. Atpresent, thereseems 
to be more evidence supporting the concept that 
gelatinase is a proenzyme that undergoes a marked 
conformational change upon activation [13]. 
Can neutrophils activate latent gelatinase? 
Little is known about the activation of latent gela- 
tinase by intact neutrophils. Gelatinase has recently 
been localized to a highly responsive, but unch- 
aracterized secretory compartment in the neutrophil 
[42,51]. Thus, it is not surprising that the limited 
number of studies on neutrophil gelatinase have 
focused on the characterization of enzyme release 
rather than its activation. However, Hibbs et al. [42] 
recently reported that neutrophils triggered with high 
concentrations of the calcium ionophore A23187 
release large amounts of active gelatinase [42]. Based 
on the fact that neutrophils appeared to have an 
endogenous activating system for gelatinase and that 
the latent enzyme has characteristics similar to those 
of latent collagenase, we initiated studies to examine 
the ability of oxidants to act as endogenous activators 
[55]. Indeed, triggered neutrophils were able to acti- 
vate a portion of their released gelatinase by an 
HOCI-dependent process. As in the interstitial col- 
lagenase system, it might be argued that HOC1 
indirectly “activated” gelatinase by destroying an 
endogenous inhibitor. However, we also demon- 
strated that highly purified latent gelatinase could be 
activated by reagent HOC1 [55]. These results sug- 
gest that neutrophils can use chlorinated oxidants to 
directly control at least one (and perhaps both) of 
their collagenolytic metalloenzymes. Structural 
analyses of the latent and HOCl-activated gelatinase 
may provide insights into the activation process at 
the molecular level. 
HOC1 played a major role in gelatinase activation, 
but antioxidants were not able to inhibit gelatinolytic 
activity by more than 75% [55]. The presence of an 
apparent HOCl-independent pathway of activation 
was confirmed in studies with chronic granulomatous 
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disease neutrophils [55]. Cells isolated from these 
individuals were able to activate gelatinase in 
amounts comparable to those detected with normal 
neutrophils that were triggered in the presence of 
antioxidants. Thus, neutrophils can activate gela- 
tinase by an &-independent pathway, but potential 
roles for endogenous or exogenous proteinases (e.g. 
cathepsin G, plasmin) or an autoactivation process 
require further study [6,13,31]. 
How are collagenases regulated in the extracellular 
space? 
Once activated, neutrophil collagenase or gela- 
tinase will continue to degrade their respective sub- 
strates unless the enzymes are inhibited or destroyed 
[6,14]. Inhibitors of collagenase activity have been 
detected in plasma, interstitial fluids, tissue extracts, 
platelets and neutrophils [6,14,56,57]. With regard 
to the tissue collagenases, most of the emphasis has 
been placed on cu-Zmacroglobulin, &l-anticol- 
lagenase and the tissue metalloproteinase inhibitors 
(TIMP). Each of these anticollagenases can effec- 
tively inhibit a variety of tissue metalloproteinases, 
but it is interesting to note that their less effective 
control of the neutrophil collagenases has not been 
stressed. Alpha-2-macroglobulin, a general plasma 
antiproteinase, has been reported to inhibit all mam- 
malian collagenases, but the rate of inhibition of 
neutrophil collagenases appears quite slow [13,58]. 
This could prove to be an important consideration in 
uiuo if neutrophil collagenase, like other mammalian 
collagenases binds to fibrillar collagen and moves 
from cleaved molecules to new substrates without 
re-equilibrating in the fluid phase [6]. 
The large size of cu-Zmacroglobulin and its relative 
exclusion from tissue sites encouraged Woolley et al. 
[59] to search for a smaller antiproteinase that could 
regulate collagenase activity in the interstitium. 
Indeed, these investigators isolated a - 40 kD serum 
protein that inhibits gastric mucosal, rheumatoid 
synovial and skin collagenase activity by 40-80%, 
but decreased neutrophil collagenase activity by only 
20% [59]. Recent studies suggest that @-l-anti- 
collagenase cross-reacts immunogically with TIMP, 
a specific metalloproteinase inhibitor synthesized by 
connective tissue cells and by megakaryocytes that 
can be detected in plasma and the platelet a-granule 
[22,56,60]. The inhibitor (or family of inhibitors) 
has been characterized as a 28.5 kD glycoprotein 
that binds and inhibits tissue collagenases by forming 
a 1: 1 complex.* However, Murphy et al. [13] 
reported that the total inhibition of purified neu- 
trophil collagenase activity by TIMP (isolated from 
bone culture media) is difficult to obtain while the 
inhibition of gelatinase occurs slowly. An analysis of 
the inhibitory activity of plasma or platelet-derived 
TIMP would be of interest since TIMP isolated from 
different tissue sources appears to block neutrophil 
collagenase and gelatinase with varying degrees of 
* TIMP has recently been sequenced and cloned in Esch- 
erichia coli [23]. Interestingly, TIMP is identical to a protein 
recently reported to have erythroid-potentiating activity 
[23]. In addition, regions of similarity have been detected 
between TIMP and the gag core proteins encoded by a 
number of retroviruses [61]. 
effectiveness [62]. Alternatively, it is possible that 
the slow inhibition of collagenases by TIMP is not a 
reflection of physiologic irrelevance, but rather a 
control mechanism that allows released collagenases 
to function extracellularly for a limited period of 
time. 
TIMP can be found in human plasma or serum, but 
Macartney and Tschesche [63-651 isolated a different 
inhibitor with characteristics very similar to those 
described for the neutrophil collagenase inhibitor. 
The circulating inhibitor has an M, of 30.5 kD, con- 
tains l-2 free thiols and inhibits a range of active 
collagenases by a process that could be regulated by 
a thiol-disulfide interchange [64,65]. Although they 
stated that the isolated inhibitor was /?-l-anti- 
collagenase, there are major differences between 
the thiol-dependent inhibitor and the collagenase 
inhibitor isolated from serum or fibroblasts 
[60,64,65]. TIMP does not contain free thiols and 
its inhibitory activity is not regulated by disulfides 
[60]. Thus, .at the very least, there are two serum 
inhibitors, one with characteristics similar to TIMP 
and a second with characteristics similar to the inhibi- 
tor found complexed with neutrophil collagenase. 
Finally, neutrophils also contain a cytosolic inhibi- 
tor of activated neutrophil collagenase [31,42]. The 
inhibitor does not react with anti-TIMP antibodies 
[56] and does not regulate collagenase activity by a 
disulfide-sensitive process [42]. If the collagenase 
inhibitors described thus far do not effectively con- 
trol the neutrophil’s metalloenzymes, it may be that 
inhibitors released from dying neutrophils ultimately 
control collagen degradation. 
A role for collagenolytic metalloenzymes in vivo? 
Although many features of neutrophil collagenase, 
neutrophil gelatinase and their endogenous inhibi- 
tors remain to be characterized, it seems clear that 
the intact cell can release and activate collagenase 
and gelatinase, two metalloenzymes that arm the cell 
with the ability to degrade type I, II, III, IV and V 
collagens. Given the fact that the primary task of the 
neutrophil is the destruction of microbes, what roles 
might be postulated for these proteinases in host 
defense? 
In response to the generation of an inflammatory 
stimulus in the extravascular tissues (e.g. an infec- 
tion), the circulating neutrophil must leave the blood 
vessel, crawl to the affected site, and ingest the 
microbe [66]. In order to reach the invaders, the 
neutrophil must first sequentially traverse a series of 
collagenous barriers including the type IV and V 
collagens associated with the endothelial cells that 
line the vascular lumen [67-691. After leaving the 
vascular bed, the neutrophil must then penetrate a 
dense network of interstitial collagens before finally 
reaching the infected site. Clearly, the order of pres- 
entation of collagenous barriers would necessitate 
the release of the appropriate collagenolytic enzyme. 
Indeed, current evidence suggests that the release of 
metalloenzymes from the neutrophil is specifically 
programmed for this type of response. Gelatinase 
and collagenase appear to be stored in at least two 
different intracellular compartments whose dis- 
charge can be separately controlled 142,511. The 
effect of increasing concentrations of chemotaxins 
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(compounds that can cause unidirectional loco- 
motion of the neutrophil along a concentration gradi- 
ent) on the release of collagenolytic metalloenzymes 
from neutrophils has been directly determined in 
vitro [42,51]. At the lowest concentrations, neu- 
trophils respond by first releasing gelatinase alone, 
but as the concentration of the chemotactic agent is 
increased (in a manner analogous to neutrophils 
moving up a concentration gradient as they migrate 
towards an infected site), both gelatinase and col- 
lagenase are released 142,511. Thus, this pattern of 
metalloenzyme release mirrors the expected order 
of presentation of their potential substrates. Despite 
the fact that so many features of this model are 
attractive (at least to us), it is surprising that so little 
data actually exist to support this scenario. What 
information is missing? What kinds of question might 
be asked? 
(1) Do neutrophils really need collagenolytic 
enzymes to penetrate the vessel wall? The basement 
membrane does not consist of collagen alone, but 
also contains a complex mixture of specific gly- 
coproteins (laminin, entactin, etc.) and heparan sul- 
fate proteoglycans [lo, 681. If the type IV and type 
V collagens associated with the endothelial cell and 
its underlying basement membrane represent only a 
portion of the connective tissue barrier that must be 
penetrated, then other matrix degrading systems may 
also be required. The C-particle compartment not 
only contains gelatinase but also includes acid hydro- 
lases and cathepsins [51]. The presence of these 
and other enzymes in this highly sensitive secretory 
compartment hints at their potential role in cell 
migration. Indeed, penetration of the basement 
membrane may require the concerted action of mul- 
tiple enzymes, including gelatinase, plasminogen 
activator, heparanase and membrane-bound serine 
proteinases, as well as the mechanical disruption of 
the matrix by the migrating cell [lo, 70-721. None- 
theless, the fact that at least three different cell 
populations capable of traversing the vascular wall, 
neutrophils, endothelial cells [73] and tumor cells 
[lo], all possess type IV and type V collagen-degrad- 
ing activity cannot be easily dismissed. Biochemical, 
immunologic, and functional analyses of the regu- 
lation of platinase and collagenase activities during 
neutrophil migration through connective tissue bar- 
riers in vitro or in uivo [67,74-761 should provide 
important insights into the role of these enzymes in 
the controlled dissolution of the basement 
membrane. 
(2) How are the metal~oenzymes regulated during 
chemotaxis? Neutrophils are able to activate gela- 
tinase or collagenase by a process dependent on 
HOCl, an oxidant potentially generated by cells 
exposed to low doses of a chemoattractant [77]. 
However, oxygen-dependent activation of the col- 
lagenases must not be an absolute requirement for 
chemotaxis because chronic granulomatous disease 
cells do not express any gross abnormalities in cell 
migration in uiuo [78]. A small portion of the 
released gelatinase can be activated by an oxygen- 
independent process in uitro, and the efficiency of 
this system under more physiolo~c conditions 
requires careful assessment. Other proenzymes are 
known to be activated by forming stoichiometric 
complexes with non-protease proteins [16,30]. The 
effects of similar interactions between the collagen- 
ases, the endothelium or basement membrane are 
unknown. Similarly, plasma factors and proteins 
could potentially activate and enhance collagenolytic 
activity [79]. Finally, the endothelium should not be 
envisioned as a passive cellular barrier that only 
covers the basement membrane. The endothelium 
may play a direct participatory role in chemotaxis 
1801, and its ability to cooperatively regulate neu- 
trophil collagenases remains an intriguing possibility. 
In order for the collagenases to mediate orderly 
basement membrane degradation during 
chemotaxis, the enzymes must be activated and then 
inhibited. For example, collagenases may require 
shielding from plasma inhibitors (TIMP, cY-Zmacro- 
globulin, /3-1-anticollagenase) in order to digest the 
basement membrane, but after the cell has migrated 
onward, the enzymes that remain tightly associated 
with the collagenous substrates must be inhibited. 
Membrane-bond collagenolytic enzymes would 
allow the neutrophil to sequester activity in the 
plasma-free en~ronment at an interface created 
between the plasma membrane and its substrate [70]. 
In addition, cell-bound enzyme would not be left 
deposited on passed substrates. However, the pres- 
ence of collagenolytic enzymes in the neutrophil 
plasma membrane has not been demonstrated nor 
would this model explain the apparent “decision” of 
the neutrophil to discharge gelatinase and col- 
lagenase into the extracellular milieu. Although 
other phagocytes may bind released proteinases to 
specific receptors on their plasma membrane, the 
ability of the neutrophil to localize enzymes in a 
similar manner is unknown 1811. Finally, the require- 
ments for the sequential utilization and inhibition of 
the collagenases could be circumvented if plasma 
inhibitors are designed to slowly inhibit the activated 
enzymes. The activation and inactivation of the col- 
lagenases released from neutrophils migrating across 
an endothelial-coated matrix in the presence of 
plasma should prove amenable to in vitro analyses. 
(3) Do metallbproteinasesparticipate in connective 
tissue degradation at the inflamed site? Once neu- 
trophils have reached the infected site, they can 
internalize the microbes and discharge additional C- 
particles and specific granules, as well as a third 
group of enzymes stored in the primary granules 
137. Thus, phagocytosable particles can stimulate the 
neutrophil to release large amounts of oxidants, col- 
lagenolytic metalloenzymes and serine proteinases, 
e.g. elastase [40,82]. This enzyme can attack cross- 
links in non-helical portions of the interstitial colla- 
gens, helical portions of type III and type IV colla- 
gens, and a variety of connective tissue glycoproteins 
and proteoglycans [14,83,84]. It is within this milieu 
that oxidants, activated metalloproteinases and ser- 
ine proteinases can form the complex “soup” that 
ultimately results in the formation of an abscess. The 
interplay between the ability of oxidants to directly 
attack collagen [85], to activate metalloproteinases, 
and to inactivate antiproteinases [40,82] versus the 
ability of elastase to attack collagens while destroying 
free collagenase or gelatinase 1133 may ultimately 
dictate the difference between physiologic and 
pathologic tissue degradation. The study of neu- 
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trophil-mediated collagen degradation in vitro 
coupled with biochemical and immunological analy- 
ses of fluids recovered from inflammatory foci in 
vitro [86] should allow investigators to elucidate the 
relative roles of these factors in tissue destruction. 
In closing, arming the neutrophil with potentially 
destructive collagenolytic mechanisms may be the 
price we pay for a mobile host defense system that 
must be able to invade any normal tissue that harbors 
pathogenic microbes. The “tricks” used by the neu- 
trophil to cross connective tissue barriers may be 
similar to those employed by migrating endothelial 
cells, fibroblasts, macrophages and even tumor cells. 
The ability of these cells to mediate tissue degra- 
dation on a small, controlled scale during migration 
may be part of the continuum of collagenase- 
mediated effects that can result in massive, uncon- 
trolled collagen destruction in inflammatory disease 
states. Studies designed to elucidate the processes by 
which neutrophils regulate their own collagenolytic 
enzymes may not only serve as a prototype for the 
study of other cell populations, but also foster the 
development of therapeutic interventions that prove 
effective in the control of inflammation, angiogenesis 
and tumor invasion. 
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